Analysts Set $7.00 Price Target for Aytu Bioscience Inc (AYTU)

Aytu Bioscience Inc (NASDAQ:AYTU) has received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.

Brokerages have set a 12 month consensus price target of $7.00 for the company and are expecting that the company will post ($0.61) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Aytu Bioscience an industry rank of 74 out of 255 based on the ratings given to related companies.

A number of research firms have commented on AYTU. Northland Securities reissued a “buy” rating on shares of Aytu Bioscience in a report on Wednesday. Zacks Investment Research lowered Aytu Bioscience from a “buy” rating to a “hold” rating in a report on Monday, March 25th.

An institutional investor recently bought a new position in Aytu Bioscience stock. Wexford Capital LP acquired a new position in Aytu Bioscience Inc (NASDAQ:AYTU) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 89,500 shares of the company’s stock, valued at approximately $71,000. Wexford Capital LP owned 1.04% of Aytu Bioscience at the end of the most recent reporting period. Institutional investors and hedge funds own 8.52% of the company’s stock.

Shares of Aytu Bioscience stock traded down $0.06 on Friday, reaching $1.67. The company’s stock had a trading volume of 372,176 shares, compared to its average volume of 2,244,427. The firm has a market cap of $20.79 million, a price-to-earnings ratio of -0.06 and a beta of 4.98. Aytu Bioscience has a 52 week low of $0.68 and a 52 week high of $13.40. The company has a current ratio of 4.72, a quick ratio of 4.37 and a debt-to-equity ratio of 0.25.

Aytu Bioscience (NASDAQ:AYTU) last posted its earnings results on Thursday, February 7th. The company reported ($0.72) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.37). The business had revenue of $1.80 million during the quarter, compared to the consensus estimate of $1.58 million. Aytu Bioscience had a negative return on equity of 95.52% and a negative net margin of 217.45%. On average, equities research analysts forecast that Aytu Bioscience will post -2.39 EPS for the current fiscal year.

Aytu Bioscience Company Profile

Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.

Featured Article: Why does a company issue an IPO?

Get a free copy of the Zacks research report on Aytu Bioscience (AYTU)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with's FREE daily email newsletter.